Long-term study of avacopan for vasculitis

This trial compares two strategies for people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have stable disease but whose ANCA blood test has become positive again. The goal is to see whether waiting and monitoring closely works as well as giving a pre-emptive dose of rituximab to prevent a flare.

This trial tests lower steroid doses for people with certain types of vasculitis that have newly affected their kidneys. The goal is to find out if a lower dose works just as well with fewer side effects.

This study looks at eye problems in people who have a disease called granulomatosis with polyangiitis (GPA), which is a type of blood vessel inflammation that can also affect the eyes. They want to understand what eye issues happen in this disease.

This study tests an oral medication called avacopan for people with active ANCA-associated vasculitis (GPA or MPA). It’s for those who need strong treatment to control their disease and aims to see if avacopan works as well as standard therapies.

This study looks at how well the drug avacopan works for people with a rare blood vessel disease called ANCA-associated vasculitis. It aims to help patients who are starting this treatment by tracking real-world results.

This trial tests a new way to deliver avacopan—a drug that reduces inflammation in rare blood vessel diseases (ANCA-associated vasculitis)—through a feeding tube instead of by mouth. The study measures how much of the drug reaches your bloodstream and checks if it's safe for patients with very severe disease who are on a breathing machine.